Spironolactone for heart failure with preserved ejection fraction

New England Journal of Medicine

Volumn 370, Issue 15, 2014, Pages 1383-1392

  Pitt, Bertram ^a   Pfeffer, Marc A ^b   Assmann, Susan F ^c   Boineau, Robin ^d   Anand, Inder S ^e   Claggett, Brian ^b   Clausell, Nadine ^f   Desai, Akshay S ^b   Diaz, Rafael ^g   Fleg, Jerome L ^d   Gordeev, Ivan ^h   Harty, Brian ^c   Heitner, John F ⁱ   Kenwood, Christopher T ^c   Lewis, Eldrin F ^b   O'Meara, Eileen ^j   Probstfield, Jeffrey L ^k   Shaburishvili, Tamaz ^l   Shah, Sanjiv J ^m   Solomon, Scott D ^b   Sweitzer, Nancy K ⁿ   Yang, Song ^d   McKinlay, Sonja M ^c   more..

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^g Estudios Clínicos Latino América and Instituto Cardiovascular de Rosario   (Argentina)

^h PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

ⁱ NEW YORK METHODIST HOSPITAL   (United States)

^j MONTREAL HEART INSTITUTE   (Canada)

^k UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^l Diagnostic Services Clinic   (Georgia)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ UNIVERSITY OF WISCONSIN MADISON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PLACEBO; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BREAST TENDERNESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSIS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HEART ARREST; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE; STROKE VOLUME; TREATMENT FAILURE;

EID: 84898713808     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1313731     Document Type: Article

References (36)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9. (Pubitemid 44079340)
2. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-9. (Pubitemid 44088349)
3. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202. (Pubitemid 36068707)
4. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768-77. (Pubitemid 47243795)
5. McMurray J, Ostergren J, Pfeffer M, et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003;5:261-70. (Pubitemid 37011854)
6. Lewis EF, Lamas GA, O'Meara E, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail 2007;9:83-91. (Pubitemid 46074490)
7. Hoekstra T, Lesman-Leegte I, van Veldhuisen DJ, Sanderman R, Jaarsma T. Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail 2011;13:1013-8.
8. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13:18-28.
9. Braunwald E. Heart failure: an update. Clin Pharmacol Ther 2013;94:430-2.
10. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:1810-52.
11. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology - developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33: 1787-847.
12. Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 2008;300:431-3. (Pubitemid 352040255)
13. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341: 709-17. (Pubitemid 29407370)
14. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
15. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. [Erratum, N Engl J Med 2003;348:2271.] (Pubitemid 36384098)
16. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013;309:781-91.
17. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004;110:558-65. (Pubitemid 39031173)
18. Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011;162(6):966.e10- 972.e10.
19. Shah SJ, Heitner JF, Sweitzer NK, et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2013;6:184-92.
20. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-9. (Pubitemid 30162810)
21. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81. (Pubitemid 37093918)
22. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-67.
23. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006;27:2338-45. (Pubitemid 44453578)
24. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27:178-86. (Pubitemid 43069034)
25. Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC, McMurray JJ. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-Preserved, and I-PRESERVE? J Am Coll Cardiol 2012; 60:2349-56.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. [Errata, JAMA 2003;289: 178, 2004;291:2196.]
27. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
28. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
29. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8. (Pubitemid 37093919)
30. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007;116:1482-7. (Pubitemid 47480639)
31. Abrahamsson P, Swedberg K, Borer JS, et al. Risk following hospitalization in stable chronic systolic heart failure. Eur J Heart Fail 2013;15:885-91.
32. Domanski M, Antman EM, McKinlay S, et al. Geographic variability in patient characteristics, treatment and outcome in an international trial of magnesium in acute myocardial infarction. Control Clin Trials 2004;25:553-62. (Pubitemid 39592860)
33. O'Connor CM, Fiuzat M, Swedberg K, et al. Influence of global region on outcomes in heart failure β-blocker trials. J Am Coll Cardiol 2011;58:915-22.
34. Blair JE, Zannad F, Konstam MA, et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol 2008;52:1640-8.
35. Pitt B, Zannad F, Gheorghiade M, et al. Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: a propensity-matched study of the EPHESUS trial. Int J Cardiol 2010;143:309-16.
36. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010;55:526-37.